Gene Therapy (2012) **19,** 956

www.nature.com/gt

CORRIGENDUM

Suicidal gene therapy in the effective control of primary human hepatocellular carcinoma as monitored by noninvasive bioimaging

KC Sia, H Huynh, N Chinnasamy, KM Hui and PYP Lam

Gene Therapy (2012) **19,** 956; doi:10.1038/gt.2012.64

Correction to: *Gene Therapy* (2012) **19**, 532–542; doi:10.1038/gt.2011.131

Since the publication of this paper, the author has noticed that several references were numbered incorrectly.

The Reference 62 found on page 539 should be reference 26.

The Correct references are now shown below:

References 1 to 16 are correct.

17 Ibrahimi A, Vande Velde G, Reumers V, Toelen J, Thiry I, Vandeputte C *et al.* Highly efficient multicistronic lentiviral vectors with peptide 2A sequences. *Hum Gene Ther* 2009; **20**: 845–860.

18 Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF *et al.* Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. *Nat Biotechnol* 2004; **22**: 589–594.

19 Nagano H. Treatment of advanced hepatocellular carcinoma: intraarterial infusion chemotherapy combined with interferon. *Oncology* 2010; **78**: 142–147.

20 Brown KS. Chemotherapy and other systemic therapies for hepatocellular carcinoma and liver metastases. *Semin Intervent Radiol* 2006; **23**: 99–108.

21 Langenbach RJ, Danenberg PV, Heidelberger C. Thymidylate synthetase: mechanism of inhibition by 5-fluoro-2′-deoxyuridylate. *Biochem Biophys Res Commun* 1972; **48**: 1565–1571.

22 Matsuoka H, Ueo H, Sugimachi K, Akiyoshi T. Preliminary evidence that incorporation of 5-fluorouracil into RNA correlates with antitumor response. *Cancer Invest* 1992; **10**: 265–269.

23 Kuriyama S, Masui K, Sakamoto T, Nakatani T, Kikukawa M, Tsujinoue H *et al.* Bystander effect caused by cytosine deaminase gene and 5-fluorocytosine in vitro is substantially mediated by generated 5-fluorouracil. *Anticancer Res* 1998; **18**: 3399–3406.

24 Cuchet D, Potel C, Thomas J, Epstein AL. HSV-1 amplicon vectors: a promising and versatile tool for gene delivery. *Expert Opin Biol Ther* 2007; **7**: 975–995.

25 Lam PY, Sia KC, Khong JH, De Geest B, Lim KS, Ho IA *et al.* An efficient and safe herpes simplex virus type 1 amplicon vector for transcriptionally targeted therapy of human hepatocellular carcinomas. *Mol Ther* 2007; **15**: 1129–1136.

26 Chinnasamy D, Milsom MD, Shaffer J, Neuenfeldt J, Shaaban AF, Margison GP *et al.* Multicistronic lentiviral vectors containing the FMDV 2A cleavage factor demonstrate robust expression of encoded genes at limiting MOI. *Virol J* 2006; **3**: 14.

27 Huynh H, Soo KC, Chow PK, Panasci L, Tran E. Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. *Clin Cancer Res* 2006; **12**: 4306–4314.

28 Kurozumi K, Hardcastle J, Thakur R, Shroll J, Nowicki M, Otsuki A *et al.* Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. *Mol Ther* 2008; **16**:1382–1391.

References 29 to 63 are correct.

The correct reference 64 is now shown below:

64 Fraefel C. Gene delivery using helper virus-free HSV-1 amplicon vectors. *Curr Protoc Neurosci* 2007; Chapter 4: Unit 4.14.